| Name | Title | Contact Details |
|---|
Montefiore St. Luke`s Cornwall (MSLC) is a not-for-profit community hospital with campuses in Newburgh and Cornwall, NY. The hospital is dedicated to serving the health care needs of the Hudson Valley and has achieved excellence in the delivery of compassionate and comprehensive health care services. The Joint Commission noted MSLC for excellence in Key Quality Measures in the management of Heart Attack, Heart Failure, Stroke and Surgical Care. MSLC is also recognized as an industry leader in using information technology to improve patient care, by winning the Most Wired Award for the fourth year in a row. In January 2018, MSLC officially became part of the Montefiore Health System to strengthen the delivery of health care locally and enhance access to exceptional specialty care for Hudson Valley residents.
L.A. Care Health Plan is a community-accountable health plan serving Los Angeles County residents through a variety of health coverage programs including L.A. Care Covered™, Medi-Cal, L.A. Care Cal MediConnect Plan and PASC-SEIU Homecare Workers Health Care Plan. L.A. Care is a leader in developing new programs through innovative partnerships designed to provide health coverage to vulnerable populations and to support the safety net. With more than 2 million members, L.A. Care is the nation`s largest publicly operated health plan.
Bodyworks Central is a Oakland, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Furiex Pharmaceuticals, Inc., a drug development company, engages in the compound partnering business primarily in the United States. It collaborates with pharmaceutical and biotechnology companies to enhance the value of their drug candidates by applying its novel approach to drug development. The company’s products under development include Eluxadoline1, a mu opioid receptor agonist and delta opioid receptor antagonist, which is in Phase III clinical trials for the treatment of diarrhea-predominant irritable bowel syndrome; and Avarofloxacin1, a Phase III-ready fluoroquinolone antibiotic for the treatment of acute bacterial skin and skin structure infections. It is also developing SYR-472, which is in Phase III clinical trials for the treatment of Type-2 diabetes. In addition, the company has rights to compounds in various stages of development and commercialization, which includes Nesina, Liovel, Oseni, and Kazano for the treatment of Type-2 diabetes, as well as Priligy for the treatment of premature ejaculation. The company was founded in 1998 and is headquartered in Morrisville, North Carolina.
The Alaska Native Tribal Health Consortium is a not-for-profit tribal health organization managed by Alaska Native tribal governments and their regional health organizations.